Integrated BioPharma revenue falls 31% in June quarter

The results narrative reports fiscal 2026 revenue of $43.9 million, while the accompanying statements list $48.872 million.

Rhea-AI Filing Summary

Integrated BioPharma, Inc. (INBP) reported results for the quarter and fiscal year ended June 30, 2026. Quarterly revenue was $9.796 million, down 31.0% from $14.175 million a year earlier; the company recorded a $0.869 million operating loss and a $1.366 million net loss, versus operating income of $0.589 million and a net loss of $0.178 million.

Fiscal-year revenue differs between the results narrative and the statements of operations: the narrative reports $43.9 million, down 19.3% from $54.4 million, while the statements list $48.872 million for 2026 and $54.353 million for 2025. The statements also show a $2.705 million operating loss and $2.842 million net loss for 2026, versus $2.020 million operating income and $0.808 million net income in 2025. The two largest customers in the Contract Manufacturing Segment represented approximately 90% of total revenue in 2026, compared with 84% in 2025.

Positive

• None.

Negative

• Quarterly revenue declined 31.0% year over year to $9.796 million.
• Fiscal-year operating results shifted from $2.020 million income to a $2.705 million loss.

Filing Explained

The June quarter's revenue exceeded cost of sales, leaving gross profit before selling and administrative expenses.

This 8-K furnishes results for the quarter and fiscal year ended June 30, 2026.

For comparable June quarters, gross profit was lower in 2026 than 2025; the 2026 figure remained after cost of sales and before selling and administrative expenses.

As of June 30, 2026, $4,471,000 in cash and equivalents equaled 340.8 days of the latest reported quarterly operating cash outflow at that quarter's rate.

Sources and calculations

• Form 8-K and furnished Exhibit 99.1 (2026-09-25)
• INBP 2026Q4 fundamentals record (2026-06-30)

• Available liquidity against the last reported quarterly operating outflow, in days at that rate $4,471,000 / ($1,194,000 / 91) = 340.8 days

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Quarterly revenue: $9.796 million Quarterly revenue decrease: 31.0% Quarterly operating loss: $0.869 million +4 more

7 metrics

Quarterly revenue $9.796 million Three months ended June 30, 2026; $14.175 million in 2025

Quarterly revenue decrease 31.0% Comparison with the quarter ended June 30, 2025

Quarterly operating loss $0.869 million Three months ended June 30, 2026; operating income of $0.589 million in 2025

Fiscal-year revenue, results narrative $43.9 million Narrative reports a 19.3% decrease from $54.4 million in fiscal 2025

Fiscal-year revenue, statements of operations $48.872 million Statements list $54.353 million for fiscal 2025

Fiscal-year net loss $2.842 million Fiscal year ended June 30, 2026; net income of $0.808 million in 2025

Revenue from two largest customers Approximately 90% Share of total revenue in fiscal 2026; 84% in fiscal 2025

Key Terms

Diluted net (loss) income per share of common stock, Weighted average common shares outstanding, Contract Manufacturing Segment

3 terms

Diluted net (loss) income per share of common stock financial

"The Company’s diluted net (loss) income per share of common stock"

Weighted average common shares outstanding financial

"Weighted average common shares outstanding"

Weighted average common shares outstanding is the average number of a company’s common stock shares that were available during a reporting period, adjusted for share issuances, buybacks, splits or conversions that happened at different times. Investors use it to fairly calculate per‑share figures like earnings per share, because it’s like averaging how many cars were on a road over time rather than counting only a snapshot—giving a truer picture of value per share.

Contract Manufacturing Segment financial

"in our Contract Manufacturing Segment"

Earnings Snapshot

Quarterly revenue: $9.796 million

Quarter and fiscal year ended June 30, 2026

Quarterly revenue $9.796 million Decrease of 31.0% from $14.175 million

Fiscal-year revenue, results narrative $43.9 million Decrease of $10.5 million or 19.3% from $54.4 million

Fiscal-year revenue, statements of operations $48.872 million Fiscal 2025 amount: $54.353 million

Fiscal-year operating loss $2.705 million Fiscal 2025 operating income: $2.020 million

Fiscal-year net loss $2.842 million Fiscal 2025 net income: $0.808 million

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was INBP's fiscal 2026 revenue?

The results narrative reports $43.9 million in fiscal 2026 revenue, while the accompanying statements of operations list $48.872 million. The narrative compares $43.9 million with $54.4 million and reports a 19.3% decrease; the statements list $54.353 million for fiscal 2025.

How much did INBP revenue fall in the June 2026 quarter?

Quarterly revenue was $9.796 million, down 31.0% from $14.175 million for the quarter ended June 30, 2025. INBP also reported a $0.869 million operating loss and a $1.366 million net loss for the 2026 quarter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/25/2026 - 05:07 PM Accepted by SEC EDGAR 09/25/2026 - 05:05 PM Learn about SEC filing dates

false 0001016504 0001016504 2026-09-25 2026-09-25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):

September 25, 2026

________________

INTEGRATED BIOPHARMA, INC.

(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

Delaware

(STATE OR OTHER JURISDICTION OF INCORPORATION)

001-31668	22-2407475
(COMMISSION FILE NUMBER)	(I.R.S. EMPLOYER IDENTIFICATION NO.)

225 Long Avenue

Hillside, New Jersey 07205

 (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

(973) 926-0816

(REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	None	None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 2.02. Results of Operations and Financial Condition.

On September 25, 2026, Integrated Biopharma, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 hereto and is hereby incorporated by reference into this Item 2.02.

The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

99.1		Press Release dated September 25, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

-1-

EXHIBIT INDEX

Exhibit		Description
99.1		Press Release dated September 25, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

-2-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INTEGRATED BIOPHARMA, INC.
Date: September 25, 2026	By:     /s/ Dina L Masi
	Dina L. Masi
	Chief Financial Officer

-3-

Exhibit 99.1

NEWS RELEASE for September 25, 2026

Contact: Dina Masi, CFO

Integrated BioPharma, Inc.

investors@ibiopharma.com

888.319.6962        

Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2026

HILLSIDE, NEW JERSEY (September 25, 2026) - Integrated BioPharma, Inc. ((OTCQX: INBP)) (the “Company” or “INBP”) reports its financial results for the quarter and fiscal year ended June 30, 2026.

Revenue for the quarter ended June 30, 2026 was $9.8 million compared to $14.2 million for the quarter ended June 30, 2025, a decrease of $4.4 million or 31.0%.  The Company had an operating loss of $0.9 million compared to operating income of approximately $0.6 million in the quarters ended June 30, 2026 and 2025, respectively. 

Revenues for the fiscal year ended June 30, 2026 were $43.9 million compared to $54.4 million for the fiscal year ended June 30, 2025, a decrease of $10.5 million or 19.3%.  The Company had an operating loss for the fiscal year ended June 30, 2026 of approximately $2.7 million compared to operating income of $2.0 million for the fiscal year ended June 30, 2025. 

For the quarters ended June 30, 2026 and 2025, the Company had a net loss of approximately $1.4 million and $0.2 million or $0.04 and $0.01 per share of common stock, respectively.  The Company’s diluted net loss per share of common stock for the quarters ended June 30, 2026 and 2025 were $0.04 and $0.01 per share of common stock, respectively.

For the fiscal year ended June 30, 2026, the Company had a net loss of approximately $2.8 million or $0.09 per share of common stock, compared with net income of approximately $0.8 million or $0.03 per share of common stock for the fiscal year ended June 30, 2025.  The Company’s diluted net (loss) income per share of common stock for the fiscal years ended June 30, 2026 and 2025 were ($0.09) and $0.03 per share of common stock, respectively. 

“Our revenue decreased by approximately 19% in our fiscal year ended June 30, 2026 from the fiscal year ended June 30, 2025 and our revenue from our two largest customers in our Contract Manufacturing Segment represented approximately 90% and 84% of total revenue in our fiscal years ended June 30, 2026 and 2025, respectively,” stated the Co-Chief Executive Officers of the Company, Riva Sheppard and Christina Kay.

A summary of our financial results for the three months and fiscal years ended June 30, 2026 and 2025 follows:

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(Unaudited)
				Three Months Ended								Fiscal Year Ended
				June 30,								June 30,
				2026				2025				2026				2025
Total revenue				$	9,796			$	14,175			$	48,872			$	54,353
Cost of sales					9,768				12,706				48,072				48,791
Gross profit					28				1,469				800				5,562
Selling and administrative expenses					897				880				3,505				3,542
Operating income					(869	)			589				(2,705	)			2,020
Other income, net					19				6				142				42
(Loss) income before income taxes					(850	)			595				(2,563	)			2,062
Income tax expense, net					516				773				279				1,254
Net (loss) income				$	(1,366	)		$	(178	)		$	(2,842	)		$	808
Net (loss) income per common share:
Basic				$	(0.04	)		$	(0.01	)		$	(0.09	)		$	0.03
Diluted				$	(0.04	)		$	(0.01	)		$	(0.09	)		$	0.03
Weighted average common shares outstanding:
Basic					31,059,610				30,622,045				31,059,610				30,295,655
Diluted					31,059,610				30,622,045				31,059,610				31,168,372

About Integrated BioPharma Inc. (INBP)

Integrated BioPharma, Inc. (“INBP”) is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at ir.ibiopharma.com.

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause the results of INBP to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally are identified by the words “expects,” “anticipates,” believes,” intends,” “estimates,” “should,” “would,” “strategy,” “plan” and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements and are not guarantees of future performance. Such statements speak only as of the date hereof, are subject to change and should not be relied upon for investment purposes.  INBP undertakes no obligation to revise or update any statements for any reasons. The risks, uncertainties and assumptions include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by INBP; changes in industry capacity; pressure on prices from competition or from purchasers of INBP’s products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to INBP; availability of qualified personnel; the loss of any significant customers or suppliers; inflation, including inflationary pressures from any tariffs, and tightened labor markets; our ability to expand our customer base and other risks and uncertainties described in the section entitled “Risk Factors” in INBP’s most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q.  Accordingly, INBP cannot give assurance that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of INBP.

Filing Exhibits & Attachments

5 documents

Press Releases

• EX-99.1 EXHIBIT 99.1 PRESS RELEASE SEPTEMBER 25 2026 74.3 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.5 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 10.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 13.5 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 10.1 KB